Acacia Pharma reports excellent results from APD403 Stage 2 study in CINV – Major Endpoint of Preventing Delayed CINV Met With High Significance Acacia Pharma Ltd , a specialty pharmaceutical business developing supportive care products for post-surgical and cancers patients in america and international markets, announces positive results from its Phase 2 research of APD403 in preventing chemotherapy-induced nausea & vomiting http://synthroiduk.org . CINV occurs in approximately 70 percent of most cancer patients getting chemotherapy and in 90 percent of those receiving highly emetogenic chemotherapy .
He, with Dr together. William Snider at the University of NEW YORK, found that the mice lacking the gene for ERK2 in neural crest cells experienced developmental defects resembling those of individual individuals with a deletion that contains this gene. The sufferers have features that act like DiGeorge syndrome, which is definitely associated with cardiac and palate defects. Interestingly, the ERK2 gene can be central to a well-known pathway already connected with a different distinctive group of cardiac and craniofacial syndromes that consist of Noonan, Costello, Cardiofaciocutaneous syndrome, and LEOPARD syndrome.